News Releases - Investor Relations - Apellis Pharmaceuticals, Inc.
WEBAugust 29, 2024 Apellis Pharmaceuticals to Present at Upcoming Investor Conferences; August 8, 2024 Apellis and Sobi Announce Positive Topline Results from Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN; August 6, 2024 Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apellis Receives Negative CHMP Opinion for Pegcetacoplan for …
WEB4 days ago · WALTHAM, Mass., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European ...
Apellis plans FDA filing after drug success in kidney trial
WEBAug 8, 2024 · Treatment with an Apellis Pharmaceuticals drug appeared to benefit people with one of two uncommon kidney diseases, according to results from a late-stage clinical trial the biotechnology company disclosed Thursday.
Apellis Announces U.S. FDA Approval of the EMPAVELI® Injector, …
WEBWALTHAM, Mass., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the U.S. Food and Drug Administration (FDA) has approved the EMPAVELI ® Injector.
Apellis Announces Corporate Restructuring to Drive Growth of …
WEBAug 29, 2023 · Apellis Announces Corporate Restructuring to Drive Growth of SYFOVRE® (pegcetacoplan injection) and EMPAVELI® (pegcetacoplan), Positioning Company for Long-Term Success. August 29, 2023. Maximizing global leadership of SYFOVRE in geographic atrophy (GA) Streamlining the EMPAVELI business and prioritizing development of systemic pegcetacoplan ...
Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results
WEBWALTHAM, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), today announced its first quarter 2024 financial results and business highlights.
Apellis Pharmaceuticals, Inc. (APLS) Latest Stock News
WEBGet the latest Apellis Pharmaceuticals, Inc. (APLS) stock news and headlines to help you in your trading and investing decisions.
News Releases - Investor Relations - Apellis Pharmaceuticals, Inc.
WEBMay 14, 2024 Apellis Pharmaceuticals Refinances Existing Debt with Up to $475 Million Non-Dilutive Credit Facility from Sixth Street. May 7, 2024 Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results.
Apellis Announces 24-Month Phase 3 Post Hoc Results Showing
WEBWALTHAM, Mass., Sept. 30, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced new data from the...
Apellis Pharmaceuticals Hold Rating Justified Amidst EU Setbacks …
WEB3 days ago · Apellis Pharmaceuticals (APLS) Company Description: Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which develops novel therapeutic compounds.
Skip to content